A Trial Using Novel Markers to Predict Malignancy in Elevated-Risk Women

This study is currently recruiting participants.
Verified October 2013 by Fred Hutchinson Cancer Research Center
Sponsor:
Collaborators:
The Marsha Rivkin Center for Ovarian Cancer Research
Canary Foundation
Swedish Medical Center
Beckman Research Institute
Cedars-Sinai Medical Center
Stanford University
Fox Chase Cancer Center
Information provided by (Responsible Party):
Fred Hutchinson Cancer Research Center
ClinicalTrials.gov Identifier:
NCT01121640
First received: May 10, 2010
Last updated: October 22, 2013
Last verified: October 2013

May 10, 2010
October 22, 2013
November 2009
June 2014   (final data collection date for primary outcome measure)
Positive predictive value of each of the two screening protocols [ Time Frame: From first screen through remaining study period ] [ Designated as safety issue: No ]
Calculated as number of women with a significant lesion identified at a protocol-indicated procedure divided by number of women with protocol-indicated surgical procedures performed.
Same as current
Complete list of historical versions of study NCT01121640 on ClinicalTrials.gov Archive Site
  • Screening compliance [ Time Frame: From first screen through remaining study period ] [ Designated as safety issue: No ]
    Calculated as number of screens performed within 3 months of date scheduled divided by number of screens scheduled.
  • Cancer related distress and health related quality of life [ Time Frame: At baseline, each screen, 6 weeks post-surgery to remove remaining ovary/ies, and 6 months after post-surgical assessment ] [ Designated as safety issue: Yes ]
    Assessed using the SF-36 scale assessing HRQOL and versions of the Impact of Events Scale assessing distress associated with worry about cancer risk, and the Cancer Worry Scale
Same as current
Not Provided
Not Provided
 
A Trial Using Novel Markers to Predict Malignancy in Elevated-Risk Women
A Randomized Controlled Trial Using Novel Markers to Predict Malignancy in Elevated-Risk Women

The Novel Markers Trial will compare the safety, feasibility and effectiveness of two different epithelial ovarian cancer screening strategies that use CA125 and add HE4 as either a first or second line screen. This study is the next step in a larger research effort to develop a blood test that can be used as a screening method for the early detection of epithelial ovarian cancer.

Epithelial ovarian cancer (EOC) is usually lethal unless it is diagnosed at an early stage, thus early detection is likely to play an important role in reducing its mortality. Within the Ovarian Specialized Programs of Research Excellence Pacific Ovarian Cancer Research Consortium (POCRC) researchers have been working for a decade to discover, develop, and validate biomarkers (proteins or substances found in blood) that could help save lives by detecting EOC early. During the last five years several biomarkers, including CA125, have been evaluated for their ability to detect EOC at an earlier stage. The best markers will now be studied in a new randomized controlled trial of ovarian cancer screening.

Interventional
Phase 1
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Screening
Epithelial Ovarian Cancer
  • Procedure: CA125 assay on Abbott Architect i1000SR platform
    Bead-based sandwich ELISA style assay
    Other Name: Abbott Architect CA125 assay
  • Procedure: HE4 assay on Architect i1000SR platform
    Bead-based sandwich ELISA style assay
    Other Name: Abbott Architect HE4 assay
  • Procedure: Transvaginal Ultrasound
    Sonogram will be obtained only if confirmatory markers are elevated. Exam is restricted to ovarian evaluation.
  • CA125 every screen, HE4 at confirmatory screen.
    CA125 will be used at every screen. Women with a parametric empirical Bayes (PEB) longitudinal algorithm score above the 90th percentile will be asked to return for early recall screening. Women with a PEB score above the 95th percentile will be referred for confirmatory measurements of CA125 and HE4. If confirmatory test results are higher than expected, a transvaginal ultrasound will be performed.
    Interventions:
    • Procedure: CA125 assay on Abbott Architect i1000SR platform
    • Procedure: HE4 assay on Architect i1000SR platform
    • Procedure: Transvaginal Ultrasound
  • CA125 and HE4 at every screen.
    CA125 and HE4 will both be used at every screen. Women with a PEB score above the 95th percentile on either CA125 or HE4 will be referred for confirmatory measurements of CA125 and HE4. If confirmatory test results are higher than expected, a transvaginal ultrasound will be performed.
    Interventions:
    • Procedure: CA125 assay on Abbott Architect i1000SR platform
    • Procedure: HE4 assay on Architect i1000SR platform
    • Procedure: Transvaginal Ultrasound

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
1208
June 2014
June 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

Risk Group 1, Women ages 25 - 80:

  • The subject has tested positive for a deleterious germ line mutation in BRCA1 or BRCA2.

Risk Group 2, Women ages 35 - 80, Pedigree conditions can be satisfied by multiple primary cancers in the same person:

  • The subject has a personal history of breast cancer diagnosed before or at age 50.
  • OR the subject has a personal history of bilateral breast cancer
  • OR the subject has one first-degree relative with breast cancer diagnosed before or at age 50.
  • OR the subject has two breast cancers in the first or second degree relatives, same lineage, with at least one breast cancer diagnosed before or at age 50.
  • OR the subject has three or more first or second degree relatives, same lineage, with breast cancer diagnosed at any age.
  • OR The family contains at least one ovarian cancer diagnosed at any age in the first or second degree relatives.
  • OR the subject is of Ashkenazi ancestry and has had breast cancer diagnosed at any age.
  • OR The subject is of Ashkenazi Jewish ethnicity and has one first or second degree relative with breast cancer diagnosed at any age (must be in the same lineage as the Ashkenazi ancestry)
  • OR The subject has a male relative with breast cancer diagnosed at any age
  • OR The subject has a personal history of a positive genetic test result for a deleterious germline mutation in the P53 gene.
  • OR The subject has tested positive for a deleterious germline mutation in one of the DNA mismatch repair (MMR) genes associated with the Hereditary Non-Polyposis Colorectal Cancer Syndrome (HNPCC, also known as Lynch Syndrome) The MMR genes include MLH1, MSH2, MSH6 and PMS2.
  • OR the subject has a first or second degree relative with an identified deleterious germline BRCA1 or BRCA2 mutation, but has not yet undergone testing herself.
  • OR the subject has a first or second degree relative with an identified deleterious germline MMR gene mutation, but has not yet undergone testing herself.
  • OR Probability of carrying a BRCA1 or BRCA2 mutation given family pedigree of breast and ovarian cancers exceeds 20% by any existing BRCA mutational probability model.

Risk Group 3, Women ages 45 - 80:

  • Have measurement of CA125, HE4, MMP7 or Mesothelin exceeding the 95th percentile;
  • OR have a relative risk of at least 2 based on the EpiRisk logistic regression model including age, family history, and other risk factors.

Exclusion Criteria:

  • Removal of both ovaries for any reason.
  • History of ovarian, fallopian tube cancer or peritoneal carcinomatosis.
  • Currently pregnant.
  • Unable or unwilling to provide informed consent.
  • Unwilling to provide the name of a physician.
  • Unwilling to sign informed consent and/or medical records release form.
  • Current untreated malignancy (other than non-melanoma skin cancer).
  • Currently receiving adjuvant chemotherapy or radiation therapy for cancer (except tamoxifen or aromatase inhibitors +/- lupron). Patients who are being treated may enroll 3 months after completion of last treatment.
  • Intraperitoneal surgery within the last 3 months (laparoscopy or laparotomy).
  • A medical condition that would place subject at risk as a result of the blood donation, including but not limited to bleeding disorders, chronic infectious disease, emphysema or serious anemia.
  • Subject has a family member who is a carrier of a BRCA or MMR gene mutation and the subject has undergone genetic testing that included the family mutation and no mutation was found, and there are no cases of ovarian cancer in the family.
Female
25 Years to 80 Years
No
Contact: Kate Watabayashi 1-800-328-1124 kwatabay@fhcrc.org
United States
 
NCT01121640
P50CA83636-01, 6973
No
Fred Hutchinson Cancer Research Center
Fred Hutchinson Cancer Research Center
  • The Marsha Rivkin Center for Ovarian Cancer Research
  • Canary Foundation
  • Swedish Medical Center
  • Beckman Research Institute
  • Cedars-Sinai Medical Center
  • Stanford University
  • Fox Chase Cancer Center
Principal Investigator: Nicole Urban, ScD Fred Hutchinson Cancer Research Center
Principal Investigator: Beth Karlan, MD Cedars-Sinai Medical Center
Fred Hutchinson Cancer Research Center
October 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP